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Abstract 
Lanthipeptides (also called lantibiotics for those with antibacterial activities) are ribosomally synthesized post-
translationally modified peptides having thioether cross-linked amino acids, lanthionines, as a structural element. 
Lanthipeptides have conceivable potentials to be used as therapeutics, however, the lack of stable, high-yield, well-
characterized processes for their sustainable production limit their availability for clinical studies and further pharma-
ceutical commercialization. Though many reviews have discussed the various techniques that are currently employed 
to produce lanthipeptides, a direct comparison between these methods to assess industrial applicability has not yet 
been described. In this review we provide a synoptic comparison of research efforts on total synthesis and in vivo 
biosynthesis aimed at fostering lanthipeptides production. We further examine current applications and propose 
measures to enhance product yields. Owing to their elaborate chemical structures, chemical synthesis of these bio-
molecules is economically less feasible for large-scale applications, and hence biological production seems to be the 
only realistic alternative.
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Background
The development of novel potent antimicrobial com-
pounds to redress clinical problems caused by Staphy-
lococci and Enterococci forms of bacteria remains a 
permanent challenge for humanity to combat the severe 
problem of antibiotic resistance. Despite the urgent 
needs for new antibiotics, only few companies are active 
in this field and a very limited number of compounds are 
under development [1] due to assumed low profits. This 
dilemma of antibiotic research demands for new strate-
gies for efficient lower cost production on one side and 
possibilities to engineer existing antibiotics for new 
activities.
In order to narrow the gap between small molecule 
drugs (which encounter the problem of low target spec-
ificity) and larger biologics (which have limited oral 
bioavailability), peptide drugs are increasingly attract-
ing wide interests as pharmaceutical agents [2]. Natu-
ral peptide products from nonribosomal and ribosomal 
synthetic sources have special structural and physico-
chemical properties which make them more accessible 
to pharmaceutical and agricultural implementations [3]. 
The plethora of information discerned from explor-
ing uncultured microbes, as well as screening diverse 
resources and targets, suggest that bacteriocins could 
plausibly be applied as alternatives to conventional anti-
biotics based on their remarkable potencies against clini-
cal targets [4]. There are clear evidences which suggest 
that class I bacteriocins (the lanthipeptides) have huge 
potentials in the health sector for future use as therapeu-
tic agents [5].
Lanthipeptides are ribosomally synthesized, polycy-
clic natural peptide products that are usually charac-
terized by the presence of the thioether cross-linked 
amino acids (2S, 6R)-lanthionine (Lan) or (2S, 3S, 6R)-
3-methyllanthionine (MeLan) [6], as well as by additional 
α,β-unsaturated amino acids, such as dehydrobutyrine 
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and dehydroalanine [7]. The stereochemistry of Lan and 
MeLan residues appear to be diversified; e.g. in the case 
of enterococcal cytolysin [8] the MeLan residues in the 
peptides have a special (2R, 3R, 6R) configuration. The 
structures of lanthipeptides derive from a precursor 
peptide by posttranslational modifications (PTMs) that 
occur within the core peptide, accomplished by modify-
ing enzymes of the lanthipeptide gene cluster (lan). An 
N-terminal leader peptide is responsible for targeting 
the unmodified precursor to the modifying enzymes, 
and may also function as a translocation signal, as well as 
keeping the modified prepeptide inactive [9]. Due to their 
peculiar biosynthesis mode and their antibacterial activi-
ties, this group of bioactive peptides was first referred to 
as lantibiotics [6], however, owing to their diverse func-
tionalities in targeting different categories of biological 
effects, they are presently referred to as lanthipeptides 
[10]. The polycyclic nature of lanthipeptides gives them 
an edge over other peptide compounds with respect to 
resistance to protease degradation [11] and limited con-
formational freedom which confers a high degree of tar-
get specificity [12].
The number of identified lanthipeptides have increased 
tremendously during the last two decades; from 26 in 
1997 [13] to more than 90 in 2012 [10], and to more than 
100 characterized peptides in 2015 [14]. Figure  1 illus-
trates the number of isolated peptides over the years 
with the highest record between 2004 and 2012. While 
the interest in applying lanthipeptides as pharmaceutical 
agents is rising, there is a strong need in the development 
of the general platform methods for their production 
in the required amounts in order to meet the demands. 
Regrettably, the isolation of these natural products from 
their native sources is an expensive time-consuming pro-
cess which results in very low yields in most cases.
Industrial peptide production is commonly based on 
three alternative technologies including solid-phase syn-
thesis, liquid-phase synthesis, and in vivo biotechnologi-
cal recombinant technology. Due to the complex nature 
of lanthipeptide structures, chemical synthetic strategies 
are challenging in economic terms, which leaves a huge 
space for the efforts of bioengineering in terms of indus-
trial scale viability and generation of derivatives from 
the natural molecules in view of their clinical actions 
[19]. Moreover, applying bioengineering techniques on 
a heterologous host provides a tool also for the charac-
terization of the biosynthetic routes, innovative ways of 
generating variants of the native product and increas-
ing product yields where classical optimization of native 
strains has failed. Latest lanthipeptides reviews spe-
cializing on their antimicrobial potentials [5], mode of 
action [15], self-defensive strategies by producers [20], 
structure–activity relationships [21], and the importance 
of biosynthetic routes on discovery and bioengineer-
ing of novel peptides [10] have discussed the previous 
research in detail. We provide here a synoptic compari-
son of research efforts on total synthesis and biological 
procedures aimed at fostering the development of lanthi-
peptides production, which to our opinion have not been 
discussed anywhere in the literature. We further examine 
ongoing applications and analyze our present perception 
of current loopholes and propose measures to enhance 
production of these bioactive molecules using consistent 
bioprocess development strategies. Meanwhile chemical 
synthesis is a logical approach for the synthesis of these 
useful products, the scale-up process for large-scale pro-
duction remains seemingly challenging due to difficulties 
in generating stereochemically accurate Lan and MeLan 
rings [22], not to mention the exceedingly low yields 
obtained in lab scales (Table  1). It is therefore highly 
likely that engineering robust biological systems for large 
scale production of these peptides is a particularly prom-
ising venture.
Structural/functional properties that influence production 
of lanthipeptides
Lanthipeptides were first classified by Jung based on 
structural characteristics into A and B types [23]. How-
ever, the discovery of novel complexities in those iso-
lated thereafter prompted Sahl’s reclassification based 
on the structural similarities of the biosynthetic machin-
ery [24]. The scheme proposed by Pag & Sahl was fur-
ther developed by Willey and van der Donk in 2007 
to include homology of the leader sequence, structure 
of the biosynthetic cluster, as well as the activity of the 
mature peptide [25]. Depicted in Fig.  2a, lanthipeptides 
can be classified into four distinct groups namely: class 

























Fig. 1 Growing number of characterized lanthipeptides over the 
years. The graph also presents data extracted from [15–17–18]
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involved in the formation of the PTMs; class II modified 
by LanM; class III modified by LanKC; and class IV by 
LanL [10]. The ‘Lan’ is a generic notation which symbol-
izes proteins that are encoded by the lan gene cluster and 
are involved in the biosynthesis and translocation of lan-
thipeptides. Unlike LanM, LanKC lacks the residues that 
are believed to coordinate the Zn2+ ion in the catalytic 
core of the lanthionine cyclase, suggesting an alternative 
catalytic pathway which should be further investigated. 
The latter information as well as the reversibility of lan-
thionine cyclase catalysis [26] could be useful for growth 
media engineering and possible thermodynamic control 
of the cyclisation reactions which may further improve 
active production of lanthipeptides in selected process 
schemes.
The biosynthetic machinery of lanthipeptides predomi-
nantly includes a two-component regulatory system with 
the histidine kinase LanK and the regulatory protein 
LanR. The ABC (ATP-binding cassette) transporter/pro-
cessing protein LanT coordinates the modifying enzymes 
with the synthesis of the channel and thus is important 
for the translocation of the bioactive peptides from the 
cell to the extracellular environment where they per-
form their intended functions. The leader peptide, which 
in most cases is attached to the core peptide (Fig. 2b), is 
subsequently removed, after the core peptide has been 
modified as mentioned earlier, by a dedicated serine pro-
tease LanP prior to secretion of the active molecule out 
of the cell [27]. In other examples like nisin [28] and epi-
dermin [29], the leader peptide cleavage and hence acti-
vation is performed extracellularly. With the exception 
of cytolysin, lanthipeptides which possess the Gly–Gly 
cleavage site in their precursor peptide are processed by 
an N-terminal protease domain of the LanT transporters 
[30]. Cytolysin undergoes a second cleavage/activation 
by a dedicated serine protease (CylP) [31] in the extra-
cellular space after exportation by its processing protein 
(CylT). The LanFEGH proteins which are characteristic 
of the class I and class II lanthipeptides perform immu-
nity roles by forming ABC-transporters that protect the 
cells from being attacked by the synthesized product [15, 
32].
The PTMs labelled in Fig.  3 are distinctively unique, 
highly specialized in their biological functions [15], and 
amongst other factors such as self-immunity, make scale-
up production of lanthipeptides in a heterologous host 
difficult since external hosts do not possess the essential 
requirements. Understanding the biosynthetic machin-
ery of lanthipeptides has resolved diverse structural 
issues that have been useful in engineering lathionine/
nonlanthionine-containing peptide variants (see below) 
as well as developing in  vitro biosynthetic techniques 
[33]. The latter approach could moreover, facilitate pro-
duction of compounds with very complex structures that 
are not readily amenable to the large-scale chemical syn-
thetic process.
Chemical synthesis
Previous and actual studies on lanthipeptide produc-
tion have focused on the total chemical synthesis 
since their relatively small sizes (commonly <40 amino 
acids) is attainable with this technique. Moreover, the 
Table 1 Chemically synthesized lanthipeptides, analogues and mimics, with corresponding yields
ND data not described
a crude product yield before HPLC purification, obtained by calculating the overall yield of the five individually synthesized ring fragments and then the yield of 
putting these fragments together as performed by Shiba [56]
Lanthipeptide, analogue  







Approx. average  
yield per step (%)
References
Nisin ND 0.003a ND 70 [56]
Lactocin S 1.5 10 71 97 [57]
Lacticin 3147 4.8 1.0–1.4 >50 >95 [22]
Lacticin 481 2.0 1.3 52 92 [35]
Epilancin 15X 2.0 1.6 59 93 [58]
DAP-substituted ring A of lactocin S 1.5 2.5 >71 93 [44]
Norleucine substituted lactocin S 0.8 0.8 >70 ND [59]
Nle, DAP-substituted lactocin S 1.0 1.8 >70 ND [59]
N-terminal oxazole lactocin S 0.33 0.3 >70 ND [59]
Alkene substituted lacticin 3147 Ltnβ 1.8 0.5 53 76 [40]
Oxygen substituted lacticin 3147 1.1 0.3 53 90 [41]
Bis(desmethyl)lacticin 3147 1.0 1.3 >50 84 [43]
LL- diastereomers of lacticin 481 1.9 1.3 >53 92 [35]
N-truncated variant of Epilancin 15X 1.2 1.9 45 92 [58]
Page 4 of 16Ongey and Neubauer  Microb Cell Fact  (2016) 15:97 
physicochemical properties of the generated product 
can be controlled via chemical synthesis by incorporat-
ing novel structural moieties [34] that could significantly 
enhance the pharmaceutical applicability. Additionally, 
the chemical synthesis is independent of the complex 
biological pathways [35] but instead relies on a standard 
technology. Thus chemical methods have been widely 
used to explore structure–activity relationships and to 
decipher the mode of action of various lanthipeptides. 
Over the last decade, information derived from these 
studies resulted in impressive achievements in developing 
this class of compounds, with a number of compounds 
which are currently under investigation or have com-
pleted phase I or phase II clinical trials, such as mutacin 
1140, microbisporicin, actagardine and duramycin.
Chemically synthesized derivatives; their activities 
and potential uses
Chemical synthesis and semisynthetic refinements of 
parent compounds are amongst the most popular tools 
used to generate the vast pool of conventional antibiot-
ics [36], and could convincingly be well exploited to pro-
duce small compounds like vancomycin and clindamycin 
which also pose some structural challenges that limit 
practical large-scale synthetic approaches [37].
The first orthogonally protected β-methyllanthionine 
was synthesized by VanNieuwenhze in 2005 [38], fol-
lowed by the solid-phase synthesis and use of orthogo-
nally protected lanthionine (Fig. 4a1) to create a nisin ring 
C analogue by Tabor’s group [39]. These achievements 
opened exciting opportunities for solid-phase peptide 
synthesis (SPPS) of lanthipeptides (Fig. 4a2), since it was 
now possible to create orthogonally protected variants 
of lanthionine and methyllanthionine (Fig.  4b) with the 
right stereochemistries. Vederas’ group pioneered the 
synthesis of the non-lanthionine-containing carbocyclic 
analogue of Lacticin 3147 β-peptide using SPPS [40]. 
Lacticin 3147 is a two-component lanthipeptide consist-
ing of two post-translationally modified components α 
and β, which act in synergy to accomplish their biological 
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Fig. 2 Summary of the major structural features in lanthipeptides biosynthesis and functions. a Schematic representation of one example of each 
class of lanthipeptide biosynthetic gene clusters, showing conserved motifs between the classes (indicated by vertical lines on designated genes 
with the same colour). Putative and characterized domains are respectively labeled: Class I (LanB, LanC), II (LanM), III (LanKC) and IV (LanL) processing 
enzymes install PTMs on their respective precursor peptides (LanA, cloured red). b Structure of ruminococcin A (LanA) precursor peptide showing 
the core peptide attached to the leader peptide and the side chains of amino acid residues that are targeted by RumM for lanthionine ring forma-
tion
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function, but their individual activities are limited. The 
Lacticin 3147 β-peptide variant however, did not show 
any activity even in synergy with the complementary 
α-peptide. Nevertheless, replacing the sulfur atoms of 
the tricyclic β-peptide of the two-component lanthipep-
tide with oxygen atoms [41] resulted in a weak biological 
activity. These strategies may be of wider use to enhance 
the pharmacokinetic properties of other peptides in this 
category in view of e.g. intestinal absorption, oral bio-
availability, distribution and half-life. Such substitutions 
may also reduce the susceptibility of the compound to 
oxidation as shown in some cases [42]; much further 
investigation is required to evaluate the interactions of 
such analogues with human cells. The vulnerability of the 
lanthionine rings to oxidation may cause some technical 
constraints on therapeutic application of lanthipeptides 
which however, could be resolved by rationally exploring 
other derivatives.
The synthesis of bis(desmethyl) lacticin 3147 A2, real-
ized by replacing the MeLan rings with Lan ring struc-
tures [43], also was a remarkable achievement with 
regards to synergism. Contrary to the alkene and oxygen 
substituted β-peptide, this variant displayed antimicro-
bial activity only in the presence of the complementary 
α-peptide. Here, the chemical synthesis provided an 
important tool to structurally differentiate between 
the separate inherent actions of the α- and β-peptides, 
respectively, and their synergistic activity. Similarly, a 
diaminopimelate (DAP)-substituted analogue of lactocin 
S (Fig. 5) was highly stable while retaining its full biologi-
cal activity [44]. Recent investigations also succeded in 
coupling lipid moieties to the C-terminal A/B rings of 
nisin to produce semisynthetic constructs with potent 
activities against methicillin-resistant Staphylococ-
cus aureus (MRSA) and vancomycin-resistant entero-
cocci (VRE) [45]. All these analogues however, require 
thorough characterization for their safe application in 
humans, animals and food.
Tabor has discussed the various methods that have 
been developed to produce derivatives of orthogonally 
protected lanthionines and mythyllanthionines in her 
recent review papers [46, 47]. The techniques developed 
by Vederas group allow the synthesis of stereochemically 
accurate lanthionines and methyllanthionines [22]. These 
strategies are easily amenable to solid supported synthe-
ses and could be further improved in large-scale scenar-
ios to facilitate automation of the lanthipeptide synthetic 
process. Kirichenko and coworkers investigated the 
schemes created by Liu and colleagues to develop a tech-
nique that enables the synthesis of a series of overlapping 
intramolecular lanthionine bridges in polypeptides [48]. 
The so-called differentially protected orthogonal lanthio-
nine technology (DPOLT) has been applied by Oragenics 
Inc. to develop a synthetic version of mutacin 1140, also 
called MU1140-S, which entered the preclinical phase 
to combat MRSA, Clostridium difficile, Mycobacterium 
tuberculosis, VRE and anthrax about half a decade ago 
[49]. Oragenics Inc. in collaboration with Intrexon Corp. 
and Bachem Americas Inc. established a joined effort to 
achieve the commercial production of MU1140-S [50]; 
according to a recent report, preclinical investigations on 
a lead clinical candidate showed an outstanding antibi-
otic efficacy [51].
Interestingly, the semisynthetic derivative of actagar-
dine, NVB302, which is more globular in nature and 
differs by two amino acids in comparison to native act-
agardine (Fig.  5), has been created [52]. NVB302 was 
modified to exclude the sulfoxide bond present in the 
parent molecule, and also a diaminoalkane was intro-
duced at the C-terminus. These modifications make the 
variant more soluble and active compared to the parent 
compound. Novacta Biosystems Ltd. began the clinical 
development of NVB302 [53], which has currently com-
pleted phase I clinical trials for the treatment of infec-
tions caused by C. difficile [54]. The same company also 
has registered patent rights for diaminoalkanes formu-
lation of this variant into appropriately coated capsules 
that allow their oral administration since the modified 
product ensures dosage integrity through the gut to the 
desired intestinal region [55]. It is evident that chemi-
cal synthesis can be used in structure–activity rela-








































Fig. 3 Major PTM features found in mature lanthipeptide. Didehy-
drobutyrine (Dhb) is derived from threonine and didehydroalanine 
(Dha) from serine. Thioether cross-linking between Dhb and cysteine 
results in methyllanthionine while that between Dha and cysteine 
gives lanthionine. The abbreviations Xn and Xn’ represent peptide 
sequences
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lanthipeptides and semisynthetic variants with enhanced 
medical significance.
‘Proof-of-concept’ approaches for the full length synthesis 
of lanthipeptides
SPPS is currently the key technology for the produc-
tion of peptides and smaller proteins with composi-
tions that are not accessible by in  vivo technologies 
for research and even for pharmaceutical applications. 
This technique had a tremendous impact on the syn-
thesis of lanthipeptides over the last decade though 
the challenges posed by structural complexities still 
prevail [46]. The first solution phase synthesis of lan-
thipeptides was realized by Shiba and colleagues for 
nisin [56]. Examples that involve SPPS include the full-
length synthesis of lactocin S [57], the total syntheses 
of both peptides of lacticin 3147 [22], analogues of 
epilancin 15X [58], and very recently lacticin 481 and 
its analogues [35]. Examples of some of the chemically 
synthesized peptides and their respective analogues 
are shown in Fig.  5, and product yields are described 
in Table 1.
Regardless of the achievements in total synthesis, the 
stereoisomeric relevance of biologically synthesized 
products and limits of chemical methods to incorporate 
all PTMs found in lanthipeptides are major concerns 
with this procedure. Considerable efforts are still needed 
to disclose ways to tackle these issues. An example 
which illustrates this challenge has been published for 
the synthesis of lacticin 481 analogues where the bio-
logical function was lost when the DL-Lan/MeLan ring 
configurations were replaced with the LL-stereoisomers 
[35]. The results in this article show that the enzymati-
cally installed lanthionines are essential for the peptides 
to retain full activity. PTMs such as the labionin rings of 
labyrinthopeptins and the S-aminovinyl-d-cysteine of the 
epidermin group are difficult to synthesize chemically. In 
fact, an attempt to synthesize the labionin rings proved to 
be challenging [60], and though chemical synthesis of the 
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Fig. 4 Simplified scheme, exemplifying chemical synthesis of lanthionine ring using OPLs. a General synthetic scheme of lanthionine ring of 
lanthipeptide involves dehydration of allyl protected serine or threonine and subsequent Michael addition reaction that couples an allyl protected 
cysteine to the dehydrated residues to form an OPL or orthogonally protected methyllanthionine respectively (1) The resultant OPL is further cou-
pled to the growing peptide chain on a resin and processed via SPPS to incorporate the desired sequence (Xn). Finally, cyclization reaction involving 
the encircled groups completes the ring formation, followed by SPPS and so on (2) The Allyl (All) protecting groups, Fmoc fluorenylmethyloxycar-
bonyl, Pmc penta-methylchromane, Aloc allyloxycarbonyl are essential in the process. The letter R (designated side chain). b Chemical structures of 
OPLs currently exploited for solid support synthesis of lanthipeptides
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for Mersacidin [61], the method uses expensive materi-
als such as palladium (Pd) catalysts which could conse-
quently significantly increase the cost of end product.
Economic feasibility of the chemical synthesis 
of lanthipeptides
Although industrial scale chemical synthesis has been 
realized for a number of peptide drugs since many years, 
the industrial scale synthesis of lanthipeptides seems not 
to be profitable yet [62], practically due to expensive raw 
materials and overall low yields which culminates into 
exorbitant production costs in large-scale scenarios. The 
total synthesis of nisin resulted in 0.003 % yield of crude 
product [56] and that of lactocin S gave an overall yield of 
10 % of the pure product in 71 reaction steps [57]. Sub-
sequent synthesis of epilancin 15X, lacticin 3147, lacticin 
481 and their analogues all resulted in product yields in 
the range of 0.3–2.5 % as shown in Table 1. Though the 
average product yields for each chemical step are oper-
ationally persuasive (70–97  %), the number of steps 
(in average between 45 and 75) are laborious and time-
consuming if the amounts of pure substances obtained 
through lab-scale synthesis (0.33–4.8 mg) are taken into 
account (Table 1).
An example for a peptide which is successfully pro-
duced by chemical synthesis is Enfuvirtide (Fuzeon, 
Hoffmann-La Roche) which is a potent anti-HIV (human 
immunodeficiency virus) drug. Its application is very 
expensive with a daily consumption of $56.42 for EU 
member states [63] and an annual cost estimate of about 
$25,000 per patient undergoing Enfuvirtide therapy in 
the United States. Enfuvirtide is however, a relatively 
small peptide (36 amino acids) with an N-terminal acety-
lation and a C-terminal amidation as the only modifica-
tions [64]. The SPPS process for Enfuvirtide production 
involves 44 reagents and 106 reaction steps with an over-
all yield of 30  % [65]. 1  kg of Enfuvirtide is obtained 
from 45  kg of raw materials [63]. The elaborate nature 
of the manufacturing process coupled with the complex 
structural properties of the peptide are the reasons for 
the very high prices on the market, which is one of the 
restrictions for the wider use of this drug. While Enfuvir-
tide is a relatively simple peptide, lanthipeptides like nisin 
for example, have seven PTMs (including 5 lanthionine 
rings, Dhb and Dha) that makes their synthesis far more 
complicated. The average product yields obtained for lan-
thipeptides on a lab-scale so far are too low, entailing a 
more expensive final product on a commercial scale com-
pared to Fuzeon, and their application as antibiotics does 
not justify a high price. In summary, chemical synthesis 
could be a faster approach to tackle pharmaceutical pro-
duction, but process scale-up is so far not economically 
feasible and hence, biological production seems to be 
the only realistic alternative. This is perhaps only true for 
natural occurring structures since no efforts have been 



















































































































































































































































































Fig. 5 Illustrative examples of chemically synthesized analogues of lanthipeptides. Posttranslationally modified residues in natural synthesis hosts 
systems are highlighted. Abu aminobutyrine
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collaboration of Oragenics with Bachem Americas to 
produce Mutacin 1140-S in large scale yielded rather 
unexpected results [66], since Bachem only succeeded 
in generating improved yield of components required to 
synthesize MU1140-S, but could not complete the pro-
cess of generating the full compound due to unexpected 
need for additional research.
Biochemical synthesis and in vivo bioengineering
A wide range of biologically engineered systems and opti-
mization strategies are currently used for the production 
of lanthipeptides, but only few industrial implementa-
tion studies are described. The major advantages of the 
biological systems include comparably high product con-
centrations, generation of the compounds in their right 
conformational geometries and very few downstream 
processing steps. Increasing knowledge and under-
standing of the key roles of various components in the 
biosynthesis of lanthipeptide, as described earlier, have 
provided enough insights on how bioengineering can be 
employed to suitably modify native strains and heterolo-
gous organisms to develop robust systems with enhanced 
production capabilities. Previous research on such 
approaches has been discussed in recent reviews [14, 62]. 
The successes of these techniques in developing process 
scale production and current applications are discussed 
herein.
Current and potential applications of bioengineered 
lanthipeptides
The very first isolated lanthipeptide nisin has a high effi-
cacy against multidrug-resistant pathogens on one side, 
and it showed a very low cytotoxicity and negligible inci-
dence of resistances under routine applications on the 
other side. However, the therapeutic use of nisin was 
restricted by its low stability (intestinal protease degrada-
tion) and its reduced solubility at physiological pH [67]. 
This explains why improving the therapeutic relevance 
of lanthipeptides is equally important in the develop-
mental process. Bioengineering of lanthipeptides is the 
major procedure currently used to modify their pharma-
cokinetic qualities and to improve their bioavailability as 
therapeutic agents. In the area of activity enhancement, 
one of the first variants of nisin Z obtained by replac-
ing the Dhb at position 2 with Dha (Fig. 6) resulted in a 
two-fold increase of the activity compared to the native 
peptide [68]. Furthermore, the Lys22Thr/Ser deriva-
tive of nisin showed a higher bioactivity and reinforced 
specificity against Listeria monocytogenes, S. aureus and 
Streptococcus agalactiae [69], while the nisin A Met21Val 
mutant showed extensive activities against C. difficile, L. 
monocytogenes, MRSA and VRE [70].
Additionally, replacing the tripeptide Ile-Dha-Leu of 
the A ring of nisin with Val-Phe-Gly resulted in a deriva-
tive with enhanced activity against the native producer 
[71], which constitutes a possible disadvantage for in vivo 
production. Nevertheless, clinically relevant bacteria 
species often possess multidrug resistance ABC trans-
porter complexes [72, 73], whose mechanisms of action 
are somewhat similar to the immunity ABC transporters 
found in the lanthipeptide producing organisms, and thus 
it is conceivable that this knowledge could be utilized to 
create peptides that would escape bacterial resistances. 
Similar mutagenesis studies and comparable results have 
also been obtained for nukacin-ISK1 [74], actagardine 
A [75] and lacticin 3147 [76]. Moreover, also a system 
for creating mersacidin derivatives with high potencies 
against MRSA, VRE and Streptococcus pneumoniae [77] 
was developed via in  vivo engineering. Though the bio-
engineered lanthipeptides have positive effects in view 
of their bioactivity on the targets, little or no report has 
been described for scale-up production. Further investi-
gations are definitely needed to develop strategies which 







































































































































Fig. 6 Illustrated examples of in vivo engineered lanthipeptides. 
The structures of nisin (showing the nisin-lipid II binding motif and 
the hinge region which are highly implicated in the activity of the 
compound), Mutacin 1140 and Nukacin-ISK1
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are well in the gram per liter range as a basis for wide-
spread pharmaceutical application.
Also the physicochemical properties of lanthipeptides 
have been dealt with accordingly. One good example is 
the nisin V Dha5Dhb variant that showed a high stabil-
ity to chemical decomposition at low pH, as well as the 
Asn27Lys and His31Lys derivatives that both had a 
four–eight fold higher solubility compared to the natu-
ral compound at pH 7 [78]. These properties could allow 
the variants to be applied at high salts concentrations. 
All these results illustrate how in vivo engineering can be 
used to create peptides with improved pharmacokinetic 
properties.
Product yields of some lanthipeptides have also been 
enhanced via in vivo engineering. For example, the muta-
cin 1140 Arg13Asp variant [79] and the His15Ser mutant 
of nukacin-ISK1 [74] both showed improved product 
yields. Another report suggests that modifying the native 
producer to restrict the cleavage of the leader peptide 
has a significant positive influence on gallidermin yields 
and obviously decreases the toxicity of the product to the 
host [80]. This result was in corroboration with Jung’s 
suggestion in 1991 [81], subsequently verified by van der 
Meer and coworkers in 1994 [82] and very recently by 
Escano and colleagues [27], that the peptide is only active 
when the leader peptide has been cleaved off. These 
understandings can pave the way through a consistent 
bioprocess development for lanthipeptide production 
since several parameters can be evaluated on the basis of 
product sufficiency with respect to host strain’s integrity.
Meanwhile the leader peptide is an essential element 
for lanthipeptide bioengineering, although in down-
stream processing it constitutes some disadvantages since 
it has to be removed from the core peptide. Accordingly, 
some researchers have dedicated their efforts to engineer 
leader peptide independent modifying enzymes, such as 
the case of LctM, which resulted in an improved analogue 
of lacticin 481 [83]. Another recently described strategy 
is based on using amber stop codon suppression tech-
nique to incorporate hydroxy acids between the leader 
peptide and the core peptide, which introduces an ester 
bonds that can be simply and specifically hydrolyzed by 
alkaline hydrolysis after the peptide has been heterolo-
gously expressed in Escherichia coli [84]. This report is 
very important since it offers a very simple solution for 
the removal of the leader peptide from the modified pre-
cursor. Moreover, other methods for removing the leader 
peptide involves mutating the residue at −1 position of 
the propeptide to Arg, Lys, or Glu, which allows the use 
commercial proteases such as trypsin, Lys-C, or GluC 
[9, 83, 85–88]. Nevertheless, this method has some dis-
advantages; e.g. mutations can alter the morphology of 
the precursor peptide resulting in low expression levels 
in heterologous hosts, decreased processing of the pre-
cursor by the modifying enzyme, and unspecific removal 
of the leader peptide after the core peptide is modified. 
Additionally, the presence of such commercial protease 
sites in the core peptide would definitely limit the appli-
cation of this procedure.
Combined bioprocess strategies and bioengineering 
strategies for increased product yields
Lanthipeptides like many other bacteriocins are mostly 
produced by Gram-positive bacteria that are frequently 
found in many commercially useful products [89]. Nature 
has evolved in a way so that these toxins are produced in 
minute quantities by the native host, primarily to be used 
as a defensive target against competition in their ecologi-
cal community. Therefore, direct cultivation and isolation 
of the biomolecules from their natural sources is chal-
lenging. Moreover, some native producers require very 
expensive medium components for growth, but studies 
have shown that such a situation can be prevented by 
engineering cultivation media; e.g. in the case of galli-
dermin the medium costs could be lowered by 93 % [90] 
and the yields were impressive as well. Whereas optimi-
zation of mutacin 1140 in minimal medium resulted in 
a hundred fold increase in yield compared to standard 
cultivation procedures [91], the outcome of this study 
only indicated that much efforts are required if large-
scale amounts of the product are required (Table  2). 
Generally, the use of complex growth media to produce 
bacteriocins is the way for large-scale production of pep-
tides which are used in the food industry for economic 
reasons [92], but due to variations in the ingredients it is 
challenging to fulfill the requirements for pharmaceuti-
cal production with complex media. Therefore, explor-
ing alternative media formulations is an interesting area 
to focus research on. Curiously, a mixed culture system 
involving grain-based extracts was used to increase nisin 
production [93] and later, a simulation-based study pro-
jected yield of about 20  g  L−1 fermentation broth using 
sweet whey and yeast extract as feedstocks [94]. These 
studies indicate that lanthipeptides could be successfully 
produced by simply using abundant and inexpensive raw 
materials.
Optimizing physicochemical parameters such as pH 
and oxygen [106], changing magnetic fields in bioreactor 
[110], and using a packed-bed bioreactor to immobilize 
native producer organisms [111] all were strategies to 
increase product yields in natural hosts. Furthermore, an 
online recovery method that utilized silicic acid to adsorb 
nisin from cultivation medium also resulted in great 
improvements in yield [112]. Moreover, an optimized 
system was developed where the entire biosynthesis path-
way of nisin was cloned into a plasmid, and expressing 
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this plasmid in a closely related nisin deficient heter-
ologous host showed a sixfold increase in yield (Table 2) 
compared to the native producer strain [95]. This kind of 
system could be very useful in producing those variants 
which tend to be toxic to producers [71]. Although opti-
mizing production in some native producers has resulted 
in increased yields for some lanthipeptides under large-
scale conditions, others have been unsuccessful as dis-
cussed in the next paragraphs.
Economic viability of bioproduction processes 
for lanthipeptides
Economically, the amounts of lanthipeptides obtained 
from the cultivation of the natural producers are rather 
too low to be viably commercialized as pharmaceuti-
cal products. For instance, the cultivations of Lactococ-
cus lactis yielded nisin in the range of 16-20 mg L−1 [16] 
under standard growth conditions. Similar outcomes 
were observed for gallidermin [100], epidermin [99], 
Lacticin 481 [107], Lacticin 3147 [109], nukacin ISK-1 
[102], epilancin 15X [97], prochlorosins [96], Ala(0)acta-
gardine [104] and mutacin 1140 [91], where the product 
yields ranged between 5.0 × 10−4 and 20 mg L−1 of cul-
ture. Although further optimization of the native strain 
consolidated approximately a thousand folds increases 
in yields for epidermin [99], gallidermin [101] and nisin 
[113], others were unsuccessful such as in the case of 
mutacin 1140 [106], epilancin 15X and lacticin 481 [98], 
where the product yields still remained in the range 
obtained by standard methods as presented in Table 2.
While all the reports described above focused on native 
producer strains, only a few studies have been performed 
on heterologous hosts probably due to restricted access 
to genetic information which are however readily avail-
able in the post genomic era. It is fascinating that engi-
neered production in E. coli significantly improved yields 
compared to those obtained from the natural source of 
nisin [96]. Also other lanthipeptides were successfully 
produced in E. coli such as prochlorosins [114] and, very 
recently, lichenicidin [19]. Nonetheless, the production 
levels of nukacin ISK-1 [103] and Ala(0)actagardine [105] 
in E. coli were lower than those observed in their respec-
tive natural hosts (see Table 2). However, with E. coli as 
the production host, it is obvious that scale-up studies 
are economically feasible since no elaborate and sophisti-
cated experimental settings are required.
The process for producing microbisporicin (NAI-107) 
by its native producer, Microbispora corallina, is the first 
reported case for industrial production of a lanthipeptide 
for use in humans as therapeutic drug. In this process 
an optimized cultivation medium is used at a 250 litre 
scale [115] to obtain kilogram-scale titers [116]. Food 
grade nisin (containing 5 % pure nisin) is currently pro-
duced by Zhejiang Silver-Elephant Bio-Engineering Co. 
at a production capacity of 100 metric ton per year and 
sold at US $100 per kilogram. The example of nisin is an 
indication that the development of stable biological pro-
duction processes of pharma grade lanthipeptides is pos-
sible and only needs more research efforts. All the other 
compounds presented in Table  3 are research-grade 
Table 2 Selected lanthipeptides, production method and  current concentration range recorded for  each designated 
method
Values were obtained from previous experiments, with special emphasis on their highest recorded yield. Entries in italic indicate yields obtained from engineering 
growth media to reduce cost
ND data not described
a value converted to mg L−1 using International Unit Converter (http://www.etoolsage.com/converter/IU_Converter.asp)
Lanthipeptide Attainable [product] (mg L−1)
Native producer  
(mg/l)
Ref. Optimized native  
producer (mg/l)
Ref. External  
host (mg/l)
Ref.
Nisin 0.178 [95]a 1.09 [95]a 24 [96]
Lichenicidins ND ND 6 [19]
Prochlorosins 5.0 × 10−4 [96] ND 1–3.5 [96]
Epilancin 15X 0.5 [97] 3.0 [98] ND
Epidermin 20 [99] 1000 [99] ND
Gallidermin 5.0 [100] 720, 200 [90, 101] ND
Nukacin ISK-1 1.06 [102] ND 1.5 [103]
Ala(0)actagardine 6.85 [104] ND 4.2 [105]
Mutacin 1140 0.1 [91] 50, 10 [91, 106] ND
Lacticin 481 0.6 [107] 1.1 [108] ND
Lacticin 3147 1.0 [109] ND ND
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qualities that are only produced in small quantities by the 
companies listed; and the prices are too high for com-
mon applications. In order to meet the requirements of a 
novel therapeutic agent, a production process for pharma 
grade lanthipeptides should accumulate costs that war-
rant a price competition between the final products and 
commercially available drugs.
Pharmaceutical prospects
Biologically produced nisin has been used as a food pre-
servative for more than five decades without any sig-
nificant incidence of microbial resistances [10]. Clinical 
studies have demonstrated possible uses of nisin as anti-
microbial films on implantable medical devices [117], 
treatment for bovine clinical mastitis caused by S. aureus 
[118, 119] and mastitis in humans [120]. Nisin–ceftriax-
one and nisin–cefotaxime have also been investigated 
for prospective use as adjunct therapies in the treatment 
of infections caused by Salmonella [121, 122]. Nisin can 
also significantly reduce biofilm formation of Enterococ-
cus faecalis in combination with penicillin, ciprofloxacin, 
and chloramphenicol [123]. Very recently, nisin has been 
shown to reduce cell proliferation in head and neck squa-
mous cell carcinoma (HNSCC) as well as in vivo tumo-
rigenesis and hence could potentially be used as a novel 
therapeutic for HNSCC [124]. Additionally, high potency 
of a nisin V has been shown in connection to various 
chemotherapies [125]. Moreover, nisin V in combination 
with colistin, has been shown to reduce cytotoxic effects 
of the very potent polymyxin antibiotic to mammalian 
cells [126]. In veterinary medicine, nisin is applied in the 
therapeutic treatment of bovine mastitis [118] and is cur-
rently produced by ImmuCell Corporation (Maine, USA) 
under the brand name Wipe Out® for the treatment of 
mastitis of lactating cows.
Duramycin from cultured cells has been produced and 
marketed by Durvet (Kansas, USA) for quite a while as an 
antibiotic for livestock. In vitro studies on nasal epithe-
lium demonstrated that duramycin increases the trans-
port of chloride ions [127], fluid secretions [128], and 
enhances the permeability of nasal membrane to chloride 
ions in healthy individuals and patients with cystic fibro-
sis [129]. Duramycin therefore has been proposed for the 
treatment of viral infections, cancers, dry eye syndrome 
and cystic fibrosis [130]. In 2007, a report on a phase II 
clinical studies on aerosolized duramycin (Moli1901) for 
the treatment of cystic fibrosis revealed exciting results 
[131]. This drug, which is jointly developed by Lantibio 
(North Carolina, USA) and AOP Orphan Pharmaceuti-
cals (Vienna, Austria) [132] has completed phase II clini-
cal trials for the treatment of cystic fibrosis [133].
The desire to improve the marketability issues in order 
to facilitate commercialization of lanthipeptides is quite 
encouraging as observed by the activities of some phar-
maceutical companies. Just recently, Oragenics (Florida, 
USA) announced a successful pre-investigational new 
drug, based on their newly bioengineered lantibiotic 
called OG253 [134]. Novacta Biosystems Ltd. on the 
other hand secured the IP for the bioengineered system 
for creating mersacidin derivatives with robust activities 
against multidrug resistant microorganisms [77]. Mean-
while, microbisporicin is presently under clinical devel-
opment by New Anti-Infective Consortium Scrl (Milan, 
Italy) and Sentinella Pharmaceuticals (New Jersey, USA) 
[135] for the treatment of C. difficile, MRSA and VRE 
[136]. At the moment, no lanthipeptide is produced and 
commercialized for therapeutic usage in humans [116] 
and therefore developing production processes that can 
sustainably deliver the products at high quality and prices 
that are comparable to conventional antibiotics is still 
interesting.
Consistent bioprocess development strategies
A recent publication has described a novel technique 
where multiple genes from a lanthipeptide biosynthesis 
cluster were isolated and reconstructed in a simple sur-
rogate expression system, E. coli [19]. This system allows 
recombinant production and secretion of the biomol-
ecules out of the cell into the cultivation medium. Thus, 
developing scale-up schemes which seek to achieve over-
production of target bioactive compounds at industrial 
scale processing could be really interesting. Rational 
high through-put bioprocess optimization using mini 
fed-batch cultivation strategies could be employed to 
enhance stable productivity of such strains. Fed-batch 
technologies exist, that allow controlled E. coli cultiva-
tion conditions already in 96-microwell plates, ensuring 
high cell densities and greater yield of target products 
[137, 138]. Such techniques conceivably present an 
attractive area that could be explored to develop robust 
Table 3 Selected lanthipeptides produced via biochemical 





Ruminococcin-A (>90 %) MyBioSource 1.8
Lacticin-481 (>90 %) MyBioSource 1.8
Mutacin 1140 (>98 %) NovoPro 0.2486
Epidermin (>98 %) NovoPro 0.2486
Nukacin ISK-1 (>98 %) NovoPro 0.3051
Plantaricin W (>98 %) NovoPro 0.3273
Lacticin 3147 (>98 %) NovoPro 0.339
Bovicin HJ50 (>98 %) NovoPro 0.3729
Actagardine (>98 %) Santa Cruz Biotechnol 0.315
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scalable bioprocess systems for producing lanthipep-
tides. This is possible since scaling up a suitably opti-
mized micro scale cultivation will require less effort. A 
good example showing the strength of this method, has 
been recently reported for the non-ribosomally synthe-
sized peptide, valinomycin. The biosynthetic pathway of 
the natural product was reconstituted in E. coli and opti-
mized to obtain a yield of more than 10  mg  L−1 in lab 
scale experiments [139] and greater than 2 mg L−1 under 
large scale processing [140]. Report elsewhere also indi-
cate that environmental factors such as pH and aeration 
may have severe impact on the activities and product 
yields of lanthipeptides [141]. These heterogeneous sce-
narios could also be rigorously investigated in a timely 
and cost-effective manner, by applying e.g. the EnBase® 
cultivation system [138] together with high through-put 
techniques such as cultivation in 96-Well sensor plates or 
mini-bioreactor systems [142] in automated liquid han-
dling platforms.
Conclusions
The lack of stable, high-yield, well-characterized pro-
cesses and generally applicable procedures for sustain-
able production limit the availability of lanthipeptides 
for clinical studies and further pharmaceutical commer-
cialization. In order to successfully develop and apply 
therapeutic lanthipeptides, the ultimate need for mass 
production processes to commercialize the product is 
very important. Ideally, chemical synthesis would pro-
duce a variety of structural analogues and also serves as 
a substitute method for producing large quantities of the 
desired product in cases where biological methods have 
been unsuccessful. However, the structural complexity of 
lanthipeptides and the combination of multiple complex 
synthetic steps make chemical production of the biomol-
ecules a challenging and painful endeavor. This further 
complicates the establishment of stable chemical pro-
cesses for large-scale synthesis.
Moreover, producing the structural elements of lanthi-
peptides in their stereochemically relevant configuration 
(which could facilitate the automation of the synthetic 
schemes) are not obviously trivial. In a nutshell, the elab-
orate structure of lanthipeptides, the exorbitant costs of 
chemical reagents, and the resultant overall low yields 
make chemical synthetic processes for lanthipeptides not 
economically viable at the moment. Additionally, a chem-
ical synthetic process is not environmentally friendly due 
to toxic substances produced such as dichloromethane, 
dimethylformamide and trifluoroacetic acid during oper-
ation; such situations could be averted by using biological 
production procedures.
Comparatively, lanthipeptides like nisin and duramycin 
are currently produced through biological processes for 
use in food and livestock, respectively. Lab-scale produc-
tion optimization of some lanthipeptides shows attrac-
tive improvements for some native producers. Some 
variants created through in vivo mutagenesis remarkably 
enhanced production and moreover, a 250 L scale indus-
trial production of microbisporicin as a therapeutic agent 
against infections caused by MRSA has been successful. 
These successes indicate the usefulness of bioprocess-
ing in targeting the manufacture of commercially viable 
therapeutic lanthipeptides. However, a general inability 
to achieve a production scale which allows for sufficient 
quantities of pure amounts of the molecules via stand-
ard lab-scale cultivation is not delightful. The results in 
terms of yields are somewhat disappointing. In order to 
overcome the challenges associated with product suf-
ficiency and commercialization of lanthipeptides, cell 
engineering would be the most productive alternative. 
In this direction, heterologous hosts such as E. coli could 
be a relatively cheaper and faster option to develop a 
robust production process for large-scale applications. 
Such engineered systems should be developed in a way 
to ensure expression of the desired product on one side 
while minimizing the metabolic load on the host on the 
other side.
High throughput bioprocess screening and optimiza-
tion of such engineered strains would ultimately lead 
to improved yields with limited labour costs. Complex 
impurities that could interfere with downstream pro-
cessing may be avoided by the use of defined media and 
by designing strains that allow the target product to be 
secreted and purified from the culture supernatant. 
Moreover, once the optimization steps are done, scale up 
for mass production is much easier and requires less time 
and effort. Peptide natural products from strictly anaero-
bic sources like Ruminococcus gnavus which are difficult 
to cultivate require a surrogate host expression system 
for the establishment of a production process. The neces-
sity for high-throughput techniques to effectively screen 
the isolated products cannot be underestimated.
Biological production and chemical syntheses both 
have useful assets that can be utilized via semisynthetic 
approaches to generate complex structural formulations 
in the bioactive peptides with enhanced therapeutic and 
pharmacological properties. However, process develop-
ment is necessary to achieve industrial scale amounts, 
which based on available data is only feasible through 
biological procedures.
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